View the EURETINA 2022 symposium on Expert clinical insights: How continuous delivery of anti-VEGF is changing the management of nAMD
Anti-VEGF therapies have redefined the care of neovascular age-related macular degeneration (nAMD). Yet, visual acuity results achieved in clinical trials may not be translated into the real-world because patients require frequent injections, which can be burdensome to patients and caregivers. This symposium highlights opportunities to improve clinical outcomes in nAMD by providing an overview of the Port Delivery System with ranibizumab (PDS), clinical safety and efficacy, implantation and refill-exchange procedures, and clinical case studies followed by an expert panel discussion.